anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During initial meeting before randomization, all patients was administered the SUDS, STAI-I, and STAI-II scales by another clinical nurse. Following this, patients were taken to a quiet, well-ventilated, and well-lit room for the BREATH breathing technique session. Following a brief training session, the BREATH technique was applied in individual sessions lasting approximately 24 min. The post-test SUDS, STAI-I, and STAI-II scales were administered by the clinical nurse.
New therapeutic agents contain (a) nicotinates of biguanides of formula R1R2N-C(=NH)-NH-C(=NH2 (I) (where R1 is 1-5C alkyl or beta-phenethyl in which the aromatic residue may be substd. by a lower alkyl gp. or a halogen atom, and R2 is H or lower alkyl), in combination with (b) the magnesium salt of clofibric acid. The agents ae hypolipaemic agents. Use of nicotinic acid in the form of its salts with (I) gives improved glucose tolerance. The hypolipaemic activity of the nicotinic acid salt is potentiated by the magnesium salt of clofibric acid. and the Mg ions promote fibrinolysis and exert central sedative and smooth muscle relaxant effects. The nicotinic acid content is reduced, thus avoiding the flushing which could otherwise occur. In an example, tablets for oral admin. contain 40 mg phenformin mononicotinate and 450 mg (b).
After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
BACKGROUND: Plasma neurofilament light chain (NFL) is a biomarker of inflammation and neurodegenerative diseases such as Alzheimer's disease (AD). However, the underlying neural mechanisms by which NFL affects cognitive function remain unclear. In this study, we investigated the effects of inflammation on cognitive integrity in patients with cognitive impairment through the functional interaction of plasma NFL with large-scale brain networks.
METHODS: This study included 29 cognitively normal, 55 LowNFL patients, and 55 HighNFL patients. Group independent component analysis (ICA) was applied to the resting-state fMRI data, and 40 independent components (IC) were extracted for the whole brain. Next, the dynamic functional network connectivity (dFNC) of each subject was estimated using the sliding-window method and k-means clustering, and five dynamic functional states were identified. Finally, we applied mediation analysis to investigate the relationship between plasma NFL and dFNC indicators and cognitive scales.
RESULTS: The present study explored the dynamics of whole-brain FNC in controls and LowNFL and HighNFL patients and highlighted the temporal properties of dFNC states in relation to psychological scales. A potential mechanism for the association between dFNC indicators and NFL levels in cognitively impaired patients.
CONCLUSIONS: Our findings suggested the decreased ability of information processing and communication in the HighNFL group, which helps us to understand their abnormal cognitive functions clinically. Characteristic changes in the inflammation-coupled dynamic brain network may provide alternative biomarkers for the assessment of disease severity in cognitive impairment patients.
The present disclosure provides a system and a method for generating an imaging report. The method may include obtaining first imaging information and second imaging information. The first and second imaging information may be acquired from an examination region of a subject using a first imaging device or a second imaging device, respectively. The method may include identifying at least one first target ROI based on the first imaging information, and determining first reporting information corresponding to the at least one first target ROI. The method may include identifying at least one second target ROI with respect to the second imaging information based on the at least one first target ROI, and determining second reporting information corresponding to the at least one second target ROI. The method may further include generating a report based on at least a part of the first reporting information or the second reporting information.
OBJECTIVE: Synovial abnormalities are modifiable targets for hand pain and osteoarthritis. We examined the prevalence and distribution of ultrasound-detected hand synovial abnormalities in a community-derived sample of older people in China.
METHODS: Within the Xiangya Osteoarthritis Study, a community-based study, we assessed synovial hypertrophy (SH), joint effusion, and Power Doppler signal (PDS) on all fingers and thumbs of both hands using standardized ultrasound examinations (score: 0-3). We assessed distribution patterns of SH and effusion using χ2-test and interrelationships of SH and effusion in different joints and hands by generalized estimating equations.
RESULTS: Among 3,623 participants (mean age: 64.4 years; women: 58.1%), prevalence of SH, effusion and PDS were 85.5%, 87.3% and 1.5%, respectively. Prevalence of SH, effusion and PDS increased with age, was higher in the right hand than in the left hand and was more common in proximal than in distal hand joints. SH and effusion often occurred in multiple joints (P < 0.001). SH in one joint was strongly associated with presence of SH in the same joint of the opposite hand (odds ratio [OR]= 6.60, 95% confidence interval [CI]: 6.19-7.03) followed by SH in other joints in the same row, (OR=5.70, 95%CI: 5.32-6.11), and then other joints in the same ray of the same hand (OR=1.49, 95%CI: 1.39-1.60). Similar patterns were observed for effusion.
CONCLUSION: Hand synovial abnormalities are common among older people, often affect multiple hand joints and present a unique pattern. These findings suggest both systemic and mechanical factors play roles in their occurrence.
Full thickness flap elevated, then elevation of sinus floor through piezoelectric surgery via intralift kit, then adding the bone graft and implant placement. Measuring the ISQ value by Ostell device, followed by flap suturing. After 6 months of implant placement exposure of implant for prosthetic phase and measuring secondary stability.
OBJECTIVE: During infection, metabolism and immunity react dynamically to promote survival through mechanisms that remain unclear. Pro-opiomelanocortin (POMC) cleavage products are produced and released in the brain and in the pituitary gland. One POMC cleavage product, alpha-melanocyte-stimulating hormone (α-MSH), is known to regulate food intake and energy expenditure and has anti-inflammatory effects. However, it is not known whether α-MSH is required to regulate physiological anti-inflammatory responses. We recently developed a novel mouse model with a targeted mutation in Pomc (Pomctm1/tm1 mice) to block production of all α-MSH forms which are required to regulate metabolism. To test whether endogenous α-MSH is required to regulate immune responses, we compared acute bacterial lipopolysaccharide (LPS)-induced inflammation between Pomctm1/tm1 and wild-type Pomcwt/wt mice.
METHODS: We challenged 10- to 14-week-old male Pomctm1/tm1 and Pomcwt/wt mice with single i.p. injections of either saline or low-dose LPS (100 μg/kg) and monitored immune and metabolic responses. We used telemetry to measure core body temperature (Tb), ELISA to measure circulating cytokines, corticosterone and α-MSH, and metabolic chambers to measure body weight, food intake, activity, and respiration. We also developed a mass spectrometry method to measure three forms of α-MSH produced in the mouse hypothalamus and pituitary gland.
RESULTS: LPS induced an exaggerated immune response in Pomctm1/tm1 compared to Pomcwt/wt mice. Both groups of mice were hypoactive and hypothermic following LPS administration, but Pomctm1/tm1 mice were significantly more hypothermic compared to control mice injected with LPS. Pomctm1/tm1 mice also had reduced oxygen consumption and impaired metabolic responses to LPS compared to controls. Pomctm1/tm1 mice had increased levels of key proinflammatory cytokines at 2 h and 4 h post LPS injection compared to Pomcwt/wt mice. Lastly, Pomcwt/wt mice injected with LPS compared to saline had increased total α-MSH in circulation 2 h post injection.
CONCLUSIONS: Our data indicate endogenous α-MSH contributes to the inflammatory immune responses triggered by low-dose LPS administration and suggest that targeting the melanocortin system could be a potential therapeutic for the treatment of sepsis or inflammatory disease.
All women with planned myomectomy receive Depo Leupron prior to surgery per standard care and undergo routine pre-operative laboratory testing including hemoglobin and hematocrit. If enrolled in the study, patients will be consented at their pre-op appointment for the study and be asked to complete a visual analog scale to assess pre-operative pain. Patients will be randomized to receive misoprostol 800mcg per rectum or an identical inert tablet(s) per rectum 30 minutes preoperatively. Randomization will be performed by a third party so that neither the surgeon nor patient will know which intervention was performed, and interventions will be placed in sealed, sequentially numbered, opaque envelopes. Researcher team will have all needed data corresponding with randomized code which will be broken at conclusion of study and will be able to match code with patient's initials and medical record number after study completion to analyze data. Myomectomy will then be performed per standard care with the use of local vasopressin to aid in decreasing blood loss per our normal standard of care.
A stable aqueous solution of hydrogen peroxide having a pH of 3-8 is produced by at least partially neutralizing an aqueous solution of an organic polymeric acid colloid and adding hydrogen peroxide thereto. Acid colloids specified are alginic acid, carboxypolymethylene compounds, partially hydrolysed polyacrylates and polymethacrylates, polyacrylic and polymethacrylic acid, and the copolymer of methylmethacrylate and methacrylic acid. Neutralization may be effected by alkali metal hydroxide, ammonia, or an amine.  The products may contain 0.1-10% of hydrogen peroxide and 0.5-5.0% of colloid salt.  Another stabilizer may be present, e.g. phenacetin or a salt of ethylene diamine tetra-acetic acid.  An example is given.ALSO:A stable aqueous solution of hydrogen peroxide having a pH of 3-8 for bleaching hair is produced by at least partially neutralizing an aqueous solution of an organic polymeric acid colloid and adding hydrogen peroxide thereto.  Acid colloids specified are alginic acid, carboxy polymethylene compounds, partially hydrolysed polyacrylates and polymethacrylates, polyacrylic and polymethacrylic acid, and the copolymer of methylmethacrylate and methacrylic acid. Neutralization may be effected by alkali metal hydroxide, ammonia, or an amine.  The products may contain 0.1-10% of hydrogen peroxide and 0.5-5.0% of colloid salt.  Another stabilizer may be present, e.g. phenacetin or a salt of ethylene diamine tetraacetic acid.  An example is given.ALSO:A stable aqueous solution of hydrogen peroxide having a pH of 3-8 for dressing wounds is produced by at least partially neutralizing an aqueous solution of an organic polymeric acid colloid and adding hydrogen peroxide thereto.  Acid colloids specified are alginic acid, carboxy polymethylene compounds, partially hydrolysed polyacrylates and polymethylates, polyacrylic and polymethacrylic acid, and the copolymer of methylmethacrylate and methacrylic acid.  Neutralization may be effected by alkali metal hydroxide, ammonia, or an amine.  The products may contain 0.1-10% of hydrogen peroxide and 0.5-5.0% of colloid salt.  Another stabilizer may be present, e.g. phenacetin or a salt of ethylene diamine tetra-acetic acid.  An example is given.
The psychoeducation program for Major Depression was also developed in the context of the previous project (PI17/00056). It consists of 12 sessions (1s/wk) in a group format and includes all aspects related to MDD (Raventós, González \& Portella. Protocolo de Psicoeducación para depresión. Ed Permanyer: Barcelona. 2020). To ensure the similarity between the two intervention arms, in the comparator arm, participants will play a previously selected mental skill game on a digital device for 20 minutes.
Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week for 8 weeks. Each session will have a duration of 60 minutes. Patients will be instructed to perform additional unsupervised sessions in at least two other days, but compliance to these extra sessions is not mandatory per protocol.
PURPOSE: A herbal extract with effects of relieving and preventing acne is provided to ensure antibacterial activity to Propionibacterium acnes. CONSTITUTION: A herbal extract has effects of relieving and preventing acne. The herbal extract includes Rhei Rhizoma, Phellodendri Cortex, Scutellariae Radix and Sophora flavescenes. The herbal extract is isolated using water, ethanol, or methanol and by performing decompression. A cosmetic composition for preventing and relieving acne contains 0.1-4 weight% of herbal extract. The cosmetic composition is used in the form of skin softener, essence, nutrition cream or pack. A skin softener for relieving and preventing acne contains 0.1-3 weight% of herbal extract, 1.5-4.5 weight% of glycine, 1.5-4.5 weight% of 1,3-butylene glycol, and 3-7 weight% of ethanol.
Some cases of chronic rhinosinusitis (CRS) require surgical treatment and postoperative nasal packing, but bleeding and adhesion are common complications after nasal surgery. Biodegradable drug-loaded implants hold great therapeutic options for the treatment of CRS, but little data are available regarding the safety and efficacy of a novel drug-loaded haemostatic sponge (DLHS) in the sinus. The aim of this study was to investigate the safety and efficacy of DLHS in the sinus. We conducted a prospective, randomized, controlled, double-blind clinical trial. In this clinical trial, 49 patients were enrolled and randomly divided into 2 groups: group A (n = 25) had the DLHS containing 1 mg budesonide and 0.67 mg sodium hyaluronate placed into the sinus, and group B (n = 24) had the Nasopore placed after ESS. Endoscopic follow-up was performed for 12 weeks, and the findings were classified using the discharge, inflammation, polyps/oedema (DIP) endoscopic appearance scores. All patients completed questionnaires to evaluate their sinonasal symptoms by using the sinonasal outcome test-22 (SNOT-22) Chinese version and visual analogue scale (VAS). Serum cortisol concentration in group A was measured prior to surgery and at days 1, 3, 7, and 14 after nasal surgery. Comparing group A and group B, at 2 weeks, no significant differences were observed in either objective or subjective parameters. The mean value of VAS for rhinorrhoea and DIP for oedema and the mean value of nasal adhesion were significantly lower in Group A than in Group B at 6 and 12 weeks, but a significant difference did not occur in SNOT-22 and VAS for dysosmia between the two groups at 6 and 12 weeks. The mean serum cortisol concentrations in group A at the follow-up were within normal limits without remarkable fluctuations. This study demonstrates the safety and efficacy of a novel biodegradable DLHS with the possibility of being used in CRS patients, and this sponge may reduce inflammation and minimize adhesions via controlled local drug delivery without measurable systemic exposure.
The objective of this research is to validate that radar MDS can accurately and predictably differentiate individuals at high-risk for MSKI from those who are low risk. The investigators hypothesize that MDS will identify individuals at a high-risk for MSKI more accurately than the gold-standard MC technologies. To test this hypothesis, the investigators propose a case control study that will compare adults who have undergone ACL reconstruction to a control group of healthy adults that has not. Patients who have undergone ACL reconstruction have a 6-24% chance of either re-tearing their ACL or having a subsequent knee surgery on either side within two years of successful completion of surgery and post-surgical rehabilitation. Despite being released for full activities, little is known about what makes this group at high-risk for re-tear. As such, the investigators will use this patient population as a model for identifying an at-risk population for musculoskeletal injury (MSKI). The researchers will simultaneously collect radar micro-Doppler signals and biomechanical motion capture (MC) data in a state-of-the-art human movement lab. Participants will be asked to perform a series of functional activities that will be captured by both the MDS radar and MC systems. The data sets will then be analyzed independently.
The study will proceed in three arms. The first group is the control group and will receive total intravenous anaesthesia as infusion after peroperative induction until the patient leaves the operating room. The second group will receive ultrasound-guided parasternal superficial plan block after induction. The third group will receive ultrasound-guided parasternal deep plan block. Extubation times, additional analgesic needs, pain scores, intensive care unit duration and hospital discharge times will be compared in the three groups during intensive care unit follow-up. After extubation, patient-controlled analgesia will be applied for 24 hours (with pca infusion pump device).
Age-related macular degeneration is a frequent eye disease in the elderly affecting the center of retina, i.e., the macula. Despite current treatments for the wet form of this disease, it is still the most frequent cause of blindness in the Western world. The disease is the result of the interplay between genetic and environmental factors such as smoking, unhealthy diet, and lack of physical activity. The current clinical recommendations are aimed towards these lifestyle factors: a healthy diet, no smoking, regular physical exercise, and use of antioxidant supplementation. Although assumed to be low by clinicians as they feel patients find it difficult to actually alter their lifestyle, the adherence and feasibility to these recommendations in clinical ophthalmology practice is unclear. Individualizing the patients' risk of blindness and lifestyle changes, as well as coaching may positively influence adherence strategies. This pilot study aims to gain knowledge and experience in a relatively small study comparing adherence to these strategies through a healthier lifestyle. Additionally, the trial investigates blood and gut microbiome biomarkers: which molecules in blood directly relate to the supplemented nutrients as well as those related to the pathogenesis of AMD, and which biomarkers in blood and eye best correlate with supplement intake and lifestyle.
Subjects will be randomized to receive either ascending doses of GSK598809 75, 120 and 175 mg or Placebo. There will be a washout period of 6 days between the doses.
Patients with permanent refractory hypoparathyroidism after total thyroidectomy will be entered in this study to undergo parathyroid transplantation from a neurologically deceased donor. Inclusion criteria are patients who have had a prior total thyroidectomy with both biochemical hypoparathyroidism and symptomatic hypocalcemia (numbness, tingling, or other neurologic symptoms) requiring daily high dose calcium (greater than 2000 mg per day), vitamin D (greater than 2 mcg of calcitriol per day) supplementation and/or intermittent IV calcium infusion. Patients for inclusion must have failed this medical management after at least 1 year of treatment and meet standard criteria for receiving organ transplant.
PURPOSE: A composition containing celastrol for preventing or treating skeletal muscle atrophy is provided to promote muscle protein synthesis and to be used in a functional sports drink. CONSTITUTION: A pharmaceutical composition for preventing or treating skeletal muscle atrophy contains celastrol as an active ingredient. The composition further contains pharmaceutically acceptable carriers. The pharmaceutical composition is manufactured in the form of powder, granules, tablets, capsules, suspensions, emulsions, syrups, liquids, aerosols, injections, or suppositories. A food composition for preventing or treating skeletal muscle atrophy contains celastrol as an active ingredient. The food composition is space food or a space food additive. A cosmetic composition for preventing or treating skeletal muscle atrophy contains celastrol as an active ingredient.
Participants will apply test product (approximately 0.6-1 grams (g)) to full face topically twice daily (morning and evening) after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
PROBLEM TO BE SOLVED: To obtain the subject hypoglycemic agent containing Sekirenka or an extract therefrom. SOLUTION: This hypoglycemic agent contains, as the main ingredient, Sekirenka belonging to the genus Keitenka (a kind of bush which naturally grows on the rocky mountain in China) or an extract therefrom. The extraction is carried out by the following process: pref. both the stems and leaves of Sekirenka are ground so as to destroy the cell wall of Sekirenka followed by extraction using a solvent such as water or an alcohol. The resulting extract (liquid) is concentrated and, as necessary, heated into powder; or, the concentrate may be purified and used. The daily dose of this agent is as follows: when the ground product of Sekirenka is to be taken directly, 3-4g/adult; while, in the form of raw powder afforded by extraction and concentration, 50-70mg/adult. This agent is useful for treating diabetes, also being effective when formulated in foods or drinks.
The present application for privileged use of the invention is aimed at the health sector and comprises a long-term re-absorbable subcutaneous implant with prolonged release of pre-concentrated pharmacologically active substance in polymer used to treat hypothyroidism. The present application involves a biodegradable implant with isolated triiodothyronine (T3), triiodothyronine sulfate (T3S), and thyroxine (T4), the association of T3 and T4, or association of T3S and T4 for treatment of hypothyroidism in a polymer matrix. The implant is inserted subcutaneously and offers continuous release of the active ingredient for an extended period of time. This extended release seeks to guarantee efficient, constant and prolonged serum levels of the drug for the treatment of hypothyroidism. The implant has a rod-shaped cylindrical format (1), provided with straight or rounded tips, and a length and diameter between 2 to 25 mm and 1 to 6 mm, respectively. The mixture of actives during manufacturing of the implant may be molded through pressure or heat so as not to compromise the efficacy of the drug or degrade the polymeric material used. Technique options for implant molding can be: injection molding, hot molding, compression molding, or extrusion molding.